Dynamics of Target-mediated Drug Disposition: Characteristic Profiles and Parameter Identification

Overview

Journal J Pharmacokinet Pharmacodyn

Publisher Springer

Specialty Pharmacology

Date 2012 Aug 2

PMID 22851162

Citations 52

Authors

Lambertus A Peletier

Johan Gabrielsson

Affiliations

Soon will be listed here.

Abstract

In this paper we present a mathematical analysis of the basic model for target mediated drug disposition (TMDD). Assuming high affinity of ligand to target, we give a qualitative characterisation of ligand versus time graphs for different dosing regimes and derive accurate analytic approximations of different phases in the temporal behaviour of the system. These approximations are used to estimate model parameters, give analytical approximations of such quantities as area under the ligand curve and clearance. We formulate conditions under which a suitably chosen Michaelis-Menten model provides a good approximation of the full TMDD-model over a specified time interval.

Citing Articles

Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY (M6495) using the neo-epitope ARGS as a biomarker.

Pereira J, Ottevaere I, Serruys B, Guehring H, Ladel C, Lindemann S J Pharmacokinet Pharmacodyn. 2024; 52(1):8.

PMID: 39704923 PMC: 11662058. DOI: 10.1007/s10928-024-09958-z.

Translational population target binding model for the anti-FcRn fragment antibody efgartigimod.

Hoefman S, van Steeg T, Ottevaere I, Baumeister J, Rossenu S J Pharmacokinet Pharmacodyn. 2024; 52(1):2.

PMID: 39636455 PMC: 11621151. DOI: 10.1007/s10928-024-09952-5.

Kinetics of RPR Decline in Pregnant Persons Treated for Syphilis in Pregnancy and Their Infants.

Schwartz D, Tse-Chang A, Robinson J, Gratrix J, Smyczek P, Hawkes M Pathogens. 2024; 13(11).

PMID: 39599563 PMC: 11597520. DOI: 10.3390/pathogens13111010.

Local depletion of large molecule drugs due to target binding in tissue interstitial space.

Zasedateleva T, Schaller S, de Lange E, de Witte W CPT Pharmacometrics Syst Pharmacol. 2024; 13(12):2068-2086.

PMID: 39530200 PMC: 11646940. DOI: 10.1002/psp4.13262.

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies.

Jiang J, Xu L, Chai L, Guan X, Zhang L, Liu H Clin Transl Sci. 2024; 17(11):e70061.

PMID: 39498965 PMC: 11536336. DOI: 10.1111/cts.70061.

References

Bauer R, Dedrick R, White M, Murray M, Garovoy M . Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 2000; 27(4):397-420. DOI: 10.1023/a:1020917122093. View

Mager D, Krzyzanski W . Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22(10):1589-96. DOI: 10.1007/s11095-005-6650-0. View

Peletier L, Benson N, van der Graaf P . Impact of plasma-protein binding on receptor occupancy: an analytical description. J Theor Biol. 2008; 256(2):253-62. DOI: 10.1016/j.jtbi.2008.09.014. View

Krippendorff B, Kuester K, Kloft C, Huisinga W . Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn. 2009; 36(3):239-60. PMC: 2718226. DOI: 10.1007/s10928-009-9120-1. View

Sugiyama Y, Hanano M . Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res. 1989; 6(3):192-202. DOI: 10.1023/a:1015905331391. View

Krzyzanski W, Wyska E . Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2007; 377(4-6):637-45. DOI: 10.1007/s00210-007-0225-z. View

Gibiansky L, Gibiansky E, Kakkar T, Ma P . Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008; 35(5):573-91. DOI: 10.1007/s10928-008-9102-8. View

Yan X, Mager D, Krzyzanski W . Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2009; 37(1):25-47. PMC: 3157300. DOI: 10.1007/s10928-009-9142-8. View

Levy G . Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994; 56(3):248-52. DOI: 10.1038/clpt.1994.134. View

10.

Gibiansky L, Gibiansky E . Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn. 2009; 36(4):341-51. DOI: 10.1007/s10928-009-9125-9. View

11.

Mager D . Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006; 72(1):1-10. DOI: 10.1016/j.bcp.2005.12.041. View

12.

Aston P, Derks G, Raji A, Agoram B, van der Graaf P . Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol. 2011; 281(1):113-21. DOI: 10.1016/j.jtbi.2011.04.030. View

13.

Marathe A, Krzyzanski W, Mager D . Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2009; 36(3):199-219. DOI: 10.1007/s10928-009-9118-8. View

14.

Mager D, Jusko W . Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res. 2002; 19(10):1537-43. DOI: 10.1023/a:1020468902694. View

15.

Shankaran H, Resat H, Wiley H . Cell surface receptors for signal transduction and ligand transport: a design principles study. PLoS Comput Biol. 2007; 3(6):e101. PMC: 1885276. DOI: 10.1371/journal.pcbi.0030101. View

16.

Segel L . On the validity of the steady state assumption of enzyme kinetics. Bull Math Biol. 1988; 50(6):579-93. DOI: 10.1007/BF02460092. View

17.

Ma P . Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res. 2011; 29(3):866-82. DOI: 10.1007/s11095-011-0615-2. View

18.

Peletier L, Gabrielsson J . Dynamics of target-mediated drug disposition. Eur J Pharm Sci. 2009; 38(5):445-64. DOI: 10.1016/j.ejps.2009.09.007. View

19.

Lobo E, Hansen R, Balthasar J . Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93(11):2645-68. DOI: 10.1002/jps.20178. View

20.

Mager D, Jusko W . General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2002; 28(6):507-32. DOI: 10.1023/a:1014414520282. View